Neurotrophic KeratitisSymptoms, Doctors, Treatments, Advances & More
Learn About Neurotrophic Keratitis
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Baylor College Of Medicine - Ophthalmology
Stephen Pflugfelder, MD, is dedicated to delivering high-quality, compassionate care to Houston and nearby communities. Stephen Pflugfelder specializes in Ophthalmology (Eye) and works at BCM Ophthalmology. To make an appointment, please call (713) 798-6100. To review all accepted insurance carriers, please visit: https://www.stlukeshealth.org/patients-visitors/patients/billing-insurance/insurances-accepted. Dr. Pflugfelder is rated as an Elite provider by MediFind in the treatment of Neurotrophic Keratitis. His top areas of expertise are Dry Eye Syndrome, Interstitial Keratitis, Giant Papillary Conjunctivitis, Dacryoadenitis, and Corneal Transplant.
Eye Consultants Of Pennsylvania PC
. Dr. Shah is rated as a Distinguished provider by MediFind in the treatment of Neurotrophic Keratitis. His top areas of expertise are Neurotrophic Keratitis, Cataract, Pterygium, and Interstitial Keratitis.
Alessandro Lambiase practices in Rome, Italy. Mr. Lambiase is rated as an Elite expert by MediFind in the treatment of Neurotrophic Keratitis. His top areas of expertise are Neurotrophic Keratitis, Giant Papillary Conjunctivitis, Interstitial Keratitis, Vitrectomy, and Corneal Transplant.
Summary: The Investigators hypothesize that the recalcitrant nature of ocular GVHD may be related to corneal nerve damage and corneal hypoesthesia. The investigators aim to study the prevalence of corneal hypoesthesia in GVHD patients and its correlation with ocular surface changes.
Summary: This is a Phase II, double-blind, placebo-controlled study to evaluate the safety and efficacy of STSP-0902 ophthalmic solution in patients with neurotrophic keratitis (NK). The study plans to enroll 48 patients with Mackie Stage 2 or 3 NK affecting one or both eyes. Eligible subjects will be randomized 1:1:1 into three dosing groups. Each dosing group will follow a drug-placebo allocation (12 act...